Molecular Partners Ag (MOLN) Other Non-Current Liabilities (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Other Non-Current Liabilities of $2458.2 for Q1 2026, down 7.76% year-on-year from $2665.0 in Q1 2025, and up 11.19% on a QoQ basis from $2210.8 in Q4 2025.
Molecular Partners Ag (MOLN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other Non-Current Liabilities for 7 consecutive years, with $2458.2 the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 7.76% year-over-year to $2458.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2458.2 (down 7.76% YoY) and the FY2025 annual result came in at $2210.8, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $2458.2 in Q1 2026 per MOLN's latest filing, from $2210.8 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for MOLN reached as high as $5.8 million in Q2 2022 and fell as low as $1497.1 in Q4 2023.
- A 5-year average of $750284.3 and a median of $2707.1 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities increased 18.94% — and 2025, when it tumbled 99.92%.
- Year by year, Other Non-Current Liabilities stood at $2224.5 in 2022, then plunged by 32.7% to $1497.1 in 2023, then surged by 83.64% to $2749.3 in 2024, then slipped by 19.59% to $2210.8 in 2025, then gained by 11.19% to $2458.2 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2458.2, $2210.8, and $2654.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,458.23 |
| Dec 31, 2025 | 2,210.82 |
| Sep 30, 2025 | 2,653.98 |
| Jun 30, 2025 | 2,380.75 |
| Mar 31, 2025 | 2,664.95 |
| Sep 30, 2024 | 2,749.32 |
| Jun 30, 2024 | 3.16 Mn |
| Mar 31, 2024 | 3,676.49 |
| Dec 31, 2023 | 1,497.13 |
| Sep 30, 2023 | 2,380.92 |
| Jun 30, 2023 | 3.05 Mn |
| Mar 31, 2023 | 3,091.04 |
| Dec 31, 2022 | 2,224.48 |
| Sep 30, 2022 | 3,539.19 |
| Jun 30, 2022 | 5.76 Mn |
| Mar 31, 2022 | 4,926.78 |
| Dec 31, 2021 | 8,013.39 |
| Sep 30, 2021 | 4,136.51 |
| Dec 31, 2020 | 6,443.36 |